Can Patients and Providers Eliminate Health Inequities in Treating Sickle Cell Disease?

Dr. Andrew Campbell shares how communities, patients, and providers can eliminate health inequities in Sickle Cell Disease (SCD). He advocates to reach out to community based organizations (CBOs), health care industry stake holders, as well as legislative representatives. Dr. Campbell asserts that if the general population is informed about SCD as a chronic and debilitating condition, then this awareness can secure resources from the National Institute of Health (NIH), fund pharmaceutical research for new drugs, and educate families. There are 100,000 SCD patients living in the US. Despite early infant screening and diagnosis, there are disparities in treatment for adult patients versus youth living with the disease. Dr. Campbell emphasizes we investigate why adult and pediatric patients are receiving different levels of care. We need more healthcare providers -- hematologists, nurse practitioners, and physician assistants – to continue care beyond pediatrics.

Dr. Andrew Campbell, Sickle Cell, CBOs, NIH, pharmaceutical research, infant screening, CASiRe, pediatric sickle cell, Children's National Health

About this expert

Andrew Campbell, MD

Director, Comprehensive Sickle Cell Program

Children’s National Health System

Director of the Consortium for the Advancement of Sickle Cell Disease Research (CASiRe)


Q: Dr. Campbell, you’ve been doing this a long time. What can communities, patients, and providers do to eliminate health inequities in SCD?

Dr. Andrew Campbell: I think joining community advisory boards -- I mean community-based organizations. So by joining community-based organizations or talking to your key stakeholders or legislative representatives in congress or other key stakeholder leaders in the healthcare industry and in the government. We need to inform the general population of this chronic debilitating condition so that it can raise awareness to the general population. That this is something that shortens your life span, it causes frequent cause of pain and continued end organ damage as you age. So that we can bring more resources from the NIH [National Institutes of Health] for example, also from the pharmaceutical companies to invest money for new drugs, for new research to understand why patients are so different from one another with the same condition. We need to inform them that this is the number one genetic condition on the United States newborn screen – over 100,000 patients living in the United States with Sickle Cell Disease. 

Dr. Andrew Campbell: We need to inform them that more of our pediatric patients in the first and second decades of life are living, but we’re struggling to keep the same level of care for our adult patients with sickle cell disease. Because sickle cell disease is an ongoing condition of end organ damage of different organs in the body leading to reduced life span. So, we feel that we have to investigate why adult patients are not having the same benefits and the same clinical picture in pediatric patients as adults. So, we need more healthcare providers, hematologists, Nurse Practitioners, PAs [Physician Assistants] to continue to carry the care for adult patients with Sickle Cell Disease because there is inequity in that.


Related Content


Microcosms of Injustice Found Throughout Sickle Cell Disease

Dr. Campbell describes the inequities and injustices throughout the sickle cell community. He presents an example of a patient who almost died because she was not listened to. Physicians must listen to patients with sickle cell disease because their complaints may be a preceding symptom of severe complications.


Is Sickle Cell Disease a Genetic Defense Against COVID-19?

Dr. Msaouel answers questions from the Sickle Cell community. If the disease or trait evolved as a defense against Malaria, does the reported effectiveness of anti-malaria drugs like hydroxychloroquine (Plaquenil) mean that sickle cell patients have natural resistance to the novel coronavirus, COVID-19?


Are Sickle Cell Disease Patients More Susceptible to Renal Medullary Carcinoma?

Dr. Pavlos Msaouel of The University of Texas MD Anderson Cancer Center discusses whether patients with sickle cell disease or who carry the sickle cell trait may be at increased risk for renal medullary carcinoma (RMC).

The information on Diverse Health Hub is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the expert advice of your healthcare team.

© 2020 Diverse Health Hub